Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.47 |
| ▸ | MME | P08473 | 4/20 | 0.47 |
| ▸ | LAP3 | P28838 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30576702 | 0.81 | ALDH1A1 (0.60) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL73762 | 0.81 | MAPT (0.60) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL2121537 | 0.81 | MAPT (0.60) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL9073861 | 0.80 | ALDH1A1 (0.75) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL7361837 | 0.79 | ALDH1A1 (0.67) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL14163018 | 0.79 | ALDH1A1 (0.67) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL7361840 | 0.79 | ALDH1A1 (0.67) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL11763161 | 0.79 | ALDH1A1 (0.72) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL11763174 | 0.79 | ALDH1A1 (0.72) | MAPTALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL15443060 | 0.77 | ALDH1A1 (0.55) | MAPTALDH1A1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | MAPT 2366/4885ALDH1A1 147/4885MEN1 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.